keyword
MENU ▼
Read by QxMD icon Read
search

Ixekizumab

keyword
https://www.readbyqxmd.com/read/28322474/efficacy-of-ixekizumab-compared-to-etanercept-and-placebo-in-patients-with-moderate-to-severe-plaque-psoriasis-and-non-pustular-palmoplantar-involvement-results-from-three-phase-3-trials-uncover-1-2-and-3
#1
A Menter, R B Warren, R G Langley, J F Merola, L N Kerr, E B Dennehy, D Shrom, D Amato, Y Okubo, K Reich
BACKGROUND: Palmoplantar psoriasis has significant physical and emotional impact on patients and can be difficult to treat. OBJECTIVE: To evaluate the efficacy of ixekizumab in the treatment of patients with moderate-to-severe non-pustular palmoplantar involvement and moderate-to-severe plaque psoriasis. METHODS: In three phase 3, double-blind, placebo-controlled trials, patients with moderate-to-severe non-pustular plaque psoriasis (UNCOVER-1 (N=1296), UNCOVER-2 (N=1224), UNCOVER-3 (N=1346)) were randomised to subcutaneous 80 mg ixekizumab every 2 or 4 weeks (Q2W, Q4W), after a 160 mg starting dose, or placebo through week 12...
March 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28319618/new-biologics-in-psoriasis-an-update-on-il-23-and-il-17-inhibitors
#2
Joanna Dong, Gary Goldenberg
As immune-related pathways involved in the pathogenesis of psoriasis are elucidated, new biologic treatments targeting these steps of the psoriatic immune cascade are developed. In this article, we review the literature on IL-23 and IL-17 inhibitors in the pipeline for use in moderate to severe psoriasis. Numerous pipeline biologic therapies, including risankizumab, guselkumab, tildrakizumab, ixekizumab, and brodalumab, are being investigated in phase 2 and 3 studies to establish the efficacy and safety of these new agents...
February 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28294430/rapid-improvements-in-health-related-quality-of-life-and-itch-with-ixekizumab-treatment-in-randomized-phase-3-trials-results-from-uncover-2-and-uncover-3
#3
C L Leonardi, A Blauvelt, H L Sofen, M Gooderham, M Augustin, R Burge, B Zhu, K Reich
BACKGROUND: Patients with moderate-to-severe psoriasis report impaired health-related quality of life (HRQoL). OBJECTIVE: To assess speed of onset of ixekizumab-induced clinically relevant improvement in HRQoL. METHODS: This post-hoc analysis used pooled data from patients randomized in UNCOVER-2 and UNCOVER-3, and treated with 80 mg ixekizumab every 2 weeks (IXEQ2W), 80 mg ixekizumab every 4 weeks (IXEQ4W), 50 mg etanercept (ETN) twice weekly, or placebo (PBO) for 12 weeks...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28288981/nice-recommends-ixekizumab-for-persistent-severe-plaque-psoriasis
#4
Susan Mayor
No abstract text is available yet for this article.
March 12, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28138946/ixekizumab-a-review-in-moderate-to-severe-plaque-psoriasis
#5
REVIEW
Yahiya Y Syed
Ixekizumab (Taltz(®)) is a subcutaneously administered, humanized anti-interleukin-17A monoclonal antibody indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (USA and EU) or phototherapy (USA). In the phase 3 UNCOVER trials in this patient population, ixekizumab was superior to placebo or etanercept in terms of the proportion of patients achieving a ≥75% reduction from baseline in the Psoriasis Area and Severity Index and in those achieving a static Physician Global Assessment score of 0 or 1, after 12 weeks of induction treatment...
February 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28074446/efficacy-and-safety-of-switching-to-ixekizumab-in-etanercept-non-responders-a-subanalysis-from-two-phase-iii-randomized-clinical-trials-in-moderate-to-severe-plaque-psoriasis-uncover-2-and-3
#6
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin
BACKGROUND: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. OBJECTIVE: Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies. METHODS: For the subanalyses in two phase III trials (UNCOVER-2 and -3), non-response was defined by either failure to have a static physician global assessment (sPGA) of 0/1 in UNCOVER-2 or failure to have at least 75% improvement in psoriasis area and severity index (PASI 75) in UNCOVER-3 at Week 12 of each study...
April 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#7
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
January 18, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28027825/inflammatory-bowel-disease-among-patients-with-psoriasis-treated-with-ixekizumab-a-presentation-of-adjudicated-data-from-an-integrated-database-of-7-randomized-controlled-and-uncontrolled-trials
#8
Kristian Reich, Craig Leonardi, Richard G Langley, Richard B Warren, Hervé Bachelez, Ricardo Romiti, Mamitaro Ohtsuki, Wen Xu, Nayan Acharya, Kathleen Solotkin, Jean-Frederic Colombel, Dana S Hardin
BACKGROUND: Inflammatory bowel disease (IBD) occurs more frequently in patients with psoriasis. The 2 diseases have significant genetic overlap, but the pathogenesis underlying their co-occurrence is unknown. OBJECTIVE: We sought to report adjudicated IBD cases (Crohn's disease [CD] and ulcerative colitis [UC]) in patients exposed to ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A. METHODS: Adverse events (AEs) integrated from 7 randomized controlled and uncontrolled trials were analyzed for the controlled induction period, controlled maintenance period, and all ixekizumab-treated patients...
December 24, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28026823/anti%C3%A2-cytokine-therapy-for-psoriasis-not-only-tnf%C3%A2-%C3%AE-blockers-overview-of-reports-on-the-effectiveness-of-therapy-with-il%C3%A2-12-il%C3%A2-23-and-t-and-b-lymphocyte-inhibitors
#9
Dominika Wcisło-Dziadecka, Martyna Zbiciak, Ligia Brzezińska-Wcisło, Urszula Mazurek
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab)...
December 8, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/27984714/il-17-blockade-in-psoriasis
#10
Patrick R Burkett, Vijay K Kuchroo
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
December 15, 2016: Cell
https://www.readbyqxmd.com/read/27971660/network-meta-analysis-to-evaluate-the-efficacy-of-ixekizumab-in-the-treatment-of-moderate-to-severe-psoriasis
#11
S Hartz, S Walzer, Y Dutronc, S Himatlal Kiri, A Schacht, H Dakin
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971619/cost-effectiveness-analysis-of-ixekizumab-vs-secukinumab-in-sequential-biologic-treatment-of-psoriasis-in-the-uk
#12
E Johansson, A Svedbom, G Kumar, S Hartz, S Kiri
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27960628/antibodies-to-watch-in-2017
#13
Janice M Reichert
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a trend toward first marketing approvals of at least 6-9 mAbs per year in the near-term. In the United States (US), a total of 6 and 9 mAbs were granted first approvals during 2014 and 2015, respectively; all these products are also approved in the European Union (EU). As of December 1, 2016, 6 mAbs (atezolizumab, olaratumab, reslizumab, ixekizumab, bezlotoxumab, oblitoxaximab) had been granted first approvals during 2016 in either the EU or US...
February 2017: MAbs
https://www.readbyqxmd.com/read/27959739/phase-3-trials-of-ixekizumab-in-moderate-to-severe-plaque-psoriasis
#14
LETTER
Alexander Egeberg
No abstract text is available yet for this article.
November 24, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959738/phase-3-trials-of-ixekizumab-in-moderate-to-severe-plaque-psoriasis
#15
LETTER
Kenneth B Gordon, Jean-Frederic Colombel, Dana S Hardin
No abstract text is available yet for this article.
November 24, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27910156/ixekizumab-treatment-improves-fingernail-psoriasis-in-patients-with-moderate-to-severe-psoriasis-results-from-the-randomized-controlled-and-open-label-phases-of-uncover-3
#16
P van de Kerkhof, L Guenther, A B Gottlieb, M Sebastian, J J Wu, P Foley, A Morita, O Goldblum, L Zhang, J Erickson, S Ball, P Rich
BACKGROUND: Fingernail psoriasis is difficult to treat. OBJECTIVE: The objective was to evaluate the effect of ixekizumab, a monoclonal antibody selectively targeting IL-17A, on fingernail psoriasis. METHODS: This Phase 3, double-blind trial (UNCOVER-3) randomized patients to placebo, etanercept (50-mg twice weekly), or 80 mg ixekizumab as one injection every 4 (IXE Q4W) or 2 weeks (IXE Q2W) after a 160-mg starting dose. At Week 12, ixekizumab patients received open-label IXE Q4W through Week 60; placebo patients received a 160-mg starting ixekizumab dose and etanercept patients a 4-week placebo washout before starting IXE Q4W...
March 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27889292/short-and-long-term-safety-outcomes-with-ixekizumab-from-7-clinical-trials-in-psoriasis-etanercept-comparisons-and-integrated-data
#17
Bruce Strober, Craig Leonardi, Kim A Papp, Ulrich Mrowietz, Mamitaro Ohtsuki, Robert Bissonnette, Laura K Ferris, Carle Paul, Mark Lebwohl, Daniel K Braun, Lotus Mallbris, Stefan Wilhelm, Wen Xu, Anders Ljungberg, Nayan Acharya, Kristian Reich
BACKGROUND: Safety of biologics is important when treating patients with psoriasis. OBJECTIVE: We sought to determine the safety of ixekizumab in psoriasis. METHODS: Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported. RESULTS: Overall, 4209 patients received ixekizumab (total exposure: 6480 patient-years)...
November 23, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27887675/clinical-efficacy-and-safety-of-ixekizumab-for-treatment-of-psoriasis
#18
A Azevedo, T Torres
Psoriasis is a common, chronic, inflammatory skin disorder with a physical and emotional burden. Emerging evidence suggests that IL17-A is a key cytokine in the immunopathogenesis of psoriasis. Ixekizumab is a humanized IgG4 monoclonal antibody that acts by neutralizing IL-17A. Data from Phase I-III studies reveal that ixekizumab is highly effective in treating patients with moderate-to-severe plaque psoriasis. A large proportion of patients receiving ixekizumab achieved or maintained complete or near complete resolution of psoriatic lesions with an acceptable safety profile through week 60...
November 22, 2016: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/27861265/drug-updates-and-approvals-2016-in-review
#19
Lindsy Meadowcraft, Geoffrey Mospan, Taylor Morrisette, Katie Smart, Melissa Janis
In 2016, the FDA approved several new drugs for use in primary care. These drugs include amphetamine extended-release orally disintegrating tablets (Adzenys XR-ODT), elbasvir and grazoprevir (Zepatier), emtricitabine and tenofovir alafenamide (Descovy), glycopyrrolate and formoterol (Bevespi Aerosphere), insulin degludec injection (Tresiba), and ixekizumab (Taltz).
December 16, 2016: Nurse Practitioner
https://www.readbyqxmd.com/read/27856660/effect-of-il-17-receptor-a-blockade-with-brodalumab-in-inflammatory-diseases
#20
REVIEW
Ajay Nirula, Jon Nilsen, Paul Klekotka, Greg Kricorian, Ngozi Erondu, Jennifer E Towne, Chris B Russell, David A Martin, Alison L Budelsky
IL-17 cytokines are expressed by a variety of cells and mediate host defence against extracellular pathogens. IL-17 is upregulated at sites of inflammation and can synergize with other cytokines, such as TNF-α, to amplify the inflammatory response. Activation of these signalling pathways has been hypothesized to contribute to the underlying pathogenesis of several inflammatory diseases, including psoriasis, RA, PsA and asthma. Thus the IL-17 signalling pathway is an attractive target for the development of therapeutic agents to modulate aberrant inflammatory responses...
December 2016: Rheumatology
keyword
keyword
64229
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"